Moberg Pharma: No surprises in the European study
Research Note
2020-06-25
09:09
Redeye maintains its base case on Moberg Pharma, in which we calculated with MOB-015 achieving non-inferiority in the European study, sufficient for registration in Europe.
GA
Gergana Almquist
Disclosures and disclaimers